[{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"S.R. One","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"SR One fuels HotSpot's $65M B round to fund allosteric R&D","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"PKC theta","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"HotSpot Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"HotSpot Therapeutics \/ S.R. One","highestDevelopmentStatusID":"2","companyTruncated":"HotSpot Therapeutics \/ S.R. One"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Pivotal bioVenture Partners","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"HotSpot Therapeutics Closes $100M Series C to Advance First-in-Class Allosteric Drug Discovery Platform to the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Cbl-b","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HotSpot Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Dosage Strength\/Form","sponsorNew":"HotSpot Therapeutics \/ Pivotal bioVenture Partners","highestDevelopmentStatusID":"3","companyTruncated":"HotSpot Therapeutics \/ Pivotal bioVenture Partners"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Caris Life Sciences and HotSpot Therapeutics Announce Collaboration to Advance Precision Medicine Development for Difficult-to-Drug Therapeutic Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HotSpot Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HotSpot Therapeutics \/ Caris Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"HotSpot Therapeutics \/ Caris Life Sciences"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HotSpot Therapeutics Presents Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Allosteric Therapy","moa":"Cbl","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"HotSpot Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"HotSpot Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"HotSpot Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Excelra","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Excelra Partners with HotSpot Therapeutics to Enhance Allosteric Drug Discovery Efforts","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"HotSpot Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HotSpot Therapeutics \/ HotSpot Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"HotSpot Therapeutics \/ HotSpot Therapeutics"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$335.0 million","upfrontCash":"$40.0 million","newsHeadline":"AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"HotSpot Therapeutics","amount2":0.34000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"HotSpot Therapeutics \/ AbbVie","highestDevelopmentStatusID":"2","companyTruncated":"HotSpot Therapeutics \/ AbbVie"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HotSpot Therapeutics Achieves First-In-Human Dosing with HST-1011, An Investigational Oral Small Molecule Allosteric Inhibitor of CBL-B","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HotSpot Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HotSpot Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"HotSpot Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HotSpot Therapeutics Announces FDA Clearance of IND Application for HST-1011, An Investigational Small Molecule Allosteric Inhibitor of CBL-B","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"HST-1011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HotSpot Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HotSpot Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"HotSpot Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by HotSpot Therapeutics

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

HotSpot Therapeutics

U.S.A

Discovery on Target

Not Confirmed

02

HotSpot Therapeutics

U.S.A

Discovery on Target

Not Confirmed

03

HotSpot Therapeutics

U.S.A

Discovery on Target

Not Confirmed

04

HotSpot Therapeutics

U.S.A

Discovery on Target

Not Confirmed

05

HotSpot Therapeutics

U.S.A

Discovery on Target

Not Confirmed

06

HotSpot Therapeutics

U.S.A

Discovery on Target

Not Confirmed

07

HotSpot Therapeutics

U.S.A

Discovery on Target

Not Confirmed

08

HotSpot Therapeutics

U.S.A

Discovery on Target

Not Confirmed